Course Overview
Statement of Need
- Diabetes affects more than 18 million Americans, and this number continues to increase among all age and ethnic groups
- Type 2 diabetes is the most prevalent form, accounting for more than 90% of all cases
- Increasing evidence indicates that impaired glucose tolerance and elevated mealtime glucose excursions (ie, postprandial glucose levels) represent an independent risk for the development of type 2 diabetes and associated cardiovascular complications
- Several therapeutic options are well suited to reduce postprandial hyperglycemia, including insulin analogs, insulin secretagogues, and agents that delay the absorption of complex carbohydrates
- Nearly 80% of people with diabetes rely on primary care physicians to help them manage their disease
- This continuing medical education (CME) teleconference series has been designed for physicians practicing internal medicine who treat patients with type 2 diabetes; the goal of the program is to add information to their knowledge base about the optimal use of available insulin therapies, alone or in combination with oral agents, so that glycemic goals can be achieved and patient outcomes improved
Course Overview
This Web cast CME program features a rebroadcast of a portion of a satellite symposium held in conjunction with the American College of Physicians (ACP) 2005 Annual Meeting in San Francisco, California
Participants will be expected to review the symposium presentations, complete the posttest, and fill out the program evaluation.
Learning Objectives
At the conclusion of this educational activity, participants should be able to:
- Describe the progressive nature of type 2 diabetes and its impact on therapeutic needs over time
- State the American Diabetes Association (ADA) and American College of Endocrinology (ACE) guidelines for patients with type 2 diabetes with regard to A1C and postprandial glucose (PPG) levels, and relate how PPG contributes to A1C
- Discuss the impact of postprandial hyperglycemia as a risk factor for other comorbidities common to patients with type 2 diabetes
Target Audience
This program is for all physicians who care for patiets with Type 2 diabetes.
CME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME
®) through the joint sponsorship of Washington Hospital Center, MedStar Research Institute, and Clinical CONNEXION. Washington Hospital Center is accredited by the ACCME to provide Continuing Medical Education programs for physicians.
Credit Designation
The Washington Hospital Center designates this educational activity for a maximum of 1.75 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Conflict of Interest Disclosure
As a sponsor accredited by the ACCME, it is the policy of Washington Hospital Center to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest prior to the educational activity. The ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of a CME activity. For an individual with no relevant financial relationship(s), the participants must be informed that no relevant financial relationship(s) exist.
All faculty are also required to disclose any discussions of unlabeled/unapproved uses of drugs or devices.
The following faculty members have indicated that they have relationships with the following companies, goods or services:
| Mansur E. Shomali, MD, CM |
Paul S. Jellinger, MD, MACE |
| |
Speaker’s Bureau:
Aventis, Novo Nordisk
Grants/Research Support:
AstraZeneca, Merck, Takeda
Honorarium:
Novo Nordisk |
Speaker’s Bureau:
Aventis, GlaxoSmithKline, Merck, Novo Nordisk, Pfizer, Takeda |
Term of Approval
| Release date: | August 2005 |
| Expiration date: | August 2007 |
| Estimated time for completion: | Approx 1 3/4 hours |
Method of Participation
This activity should take about 1 3/4 hours to complete. The participant should, in order, review the learning objectives and symposium presentation, answer the posttest questions, and complete the evaluation. The evaluation provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, and the perception of commercial bias. To receive category 1 AMA PRA credit for this activity, participants should complete the posttest and evaluation form and follow the instructions for submission. Credit will be granted through August 2007.
Content copyright 2005
All rights reserved.
